JointHealth™ express October 5, 2010
Correction to July's issue of JointHealth™ monthly
A small error was made in the French version of the July 2010 edition of JointHealth™ monthly, the issue that contains our updated Report Card On Provincial Formulary Reimbursement Listings for Biologic Response Modifiers and JointHealth™ Arthritis Medications Guide. The mistake, located within the newsletter in a sidebar entitled, "New biologics 'on the block'", was to the dosage amount of tocilizumab (Actemra®). It was stated that the medication is "taken by two intravenous infusions (or "IV") every 4 weeks" when in fact the medication is taken by only one intravenous infusion every 4 weeks.
We apologize for the error and hope that it did not cause any inconvenience.
Click to read the July 2010 JointHealth™ monthly.
Correction to July's issue of JointHealth™ monthly
A small error was made in the French version of the July 2010 edition of JointHealth™ monthly, the issue that contains our updated Report Card On Provincial Formulary Reimbursement Listings for Biologic Response Modifiers and JointHealth™ Arthritis Medications Guide. The mistake, located within the newsletter in a sidebar entitled, "New biologics 'on the block'", was to the dosage amount of tocilizumab (Actemra®). It was stated that the medication is "taken by two intravenous infusions (or "IV") every 4 weeks" when in fact the medication is taken by only one intravenous infusion every 4 weeks.
We apologize for the error and hope that it did not cause any inconvenience.
Click to read the July 2010 JointHealth™ monthly.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.